The Way Wall Street Experts See Rexahn Pharmaceuticals, Inc. (RNN)

Agilent Technologies, Inc. (NYSE:A) [Trend Analysis] tries to capture market sentiments, shares decreased -0.22% to $50.36. (NYSEMKT:RNN) where 1 analyst have rated the stock as Strong Buy, 1 analysts said it's a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. Looking at the past 52 week period, the stock price is down -43.77%. The Monthly and Yearly performances are 25.76 percent and -44.82 percent respectively.

A number of analysts offered their Estimated Earnings analysis for Forum Energy Technologies, Inc. 19 analysts projected on average Earnings. The 52-week high of the share price is $0.4245 and the company has a market cap of $48 million.

Price Target plays a critical role when it comes to the Analysis of a Stock. There may be various price targets for a stock. (NYSE:FET) share price Fell -9.67% to reach $21.95 during the last trading session. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of 17.38%. The stock hit its 52-Week High on Feb 10, 2017 and 52-Week Low on Feb 16, 2016. The company had a trading volume of 1,378,767 shares. The company's P/E is 0 and Forward P/E ratio is 0.

The company shows its Return on Assets (ROA) value of -49.7%.

Rexahn Pharmaceuticals, Inc.s in-depth stock price analysis indicates that the stock price has rallied 6.04% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -18.59%. The latest initiating coverage report came from MLV & Co on Mar 20, 2015. The stock gained a consensus recommendation of 1 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The highest and lowest price target given by the brokerage firms to the equity are $3 and $2, respectively. (NYSEMKT:RNN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Anson Funds Management LP bought a new stake in shares of Rexahn Pharmaceuticals, Inc. The stock tumbled -22.59 percent over the last 6 months. The company reported the earnings of $-0.01/Share in the last quarter where the estimated EPS by analysts was $-0.02/share.

The stock is now trading at a distance of 17.38% from SMA-20.

The stock now has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. (NYSEMKT:RNN) could bring EPS of $-0.02/share. The high end of the earnings forecast is $-0.02 per share and low end is $-0.03 per share.

For the next year first quarter, analysts predicted EPS estimates trend of $-0.02 which would leave an impact on the stock performance in coming months.

Latest News